title: Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma.
abstract: OBJECTIVE
  The purpose of this study was to assess humoral response to influenza vaccine in patients (pts) with non-Hodgkin lymphoma (NHL) as compared to healthy subjects (ctrl).
  
  
  METHODS
  In two epidemic seasons, 2003/2004 and 2004/2005, 163 pts and 92 ctrl were vaccinated. Antibody titers to hemagglutinin (HA) and neuraminidase (NA) were measured in serum samples collected before vaccination, and 1 and 6 months apart. Changes in antibody titers were assessed by comparing geometric mean titers (GMT), mean fold increases (MFI), and seroprotection and seroresponse rates to baseline values.
  
  
  RESULTS
  Pts vaccinated in 2003/2004 had, after 1 month, increase in GMT by a factor of 8.64-26.60 for antihemagglutinin antibodies (HI) and 6.93-12.66 for antineuraminidase antibodies (NI), as compared to factor of 9.12-24.41 for HI and 4.83-10.31 for NI in ctrl. At 1 month after vaccination, seroprotection and seroresponse rates were similar in both groups, ranging from 68.42 to 84.21% and 71.93 to 94.74% in NHL, and 66.67-82.22% and 62.22-86.67% in ctrl, respectively. Pts vaccinated in 2004/2005 had increase in the GMT by a factor of 38.76-41.49 for HI and 26.59-30.31 for NI, as compared to factor of 81.19-104.32 for HI and 52.16-54.52 for NI in ctrl. Seroprotection and seroresponse rates were lower in the former group, ranging from 62.11 to 65.26% and 74.47 to 77.66%, respectively. In both seasons, pts achieved titres of antibodies greater than the protective threshold, irrespective of the previous chemotherapy administration.
  
  
  CONCLUSIONS
  The results indicate that influenza vaccination induces sufficient immune response in pts with NHL, irrespective of previous chemotherapy.
authors.affiliation: Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
authors.forename: Piotr
authors.initials: P
authors.lastname: Centkowski
authors.forename: Lidia
authors.initials: L
authors.lastname: Brydak
authors.forename: Magdalena
authors.initials: M
authors.lastname: Machała
authors.forename: Ewa
authors.initials: E
authors.lastname: Kalinka-Warzocha
authors.forename: Maria
authors.initials: M
authors.lastname: Błasińska-Morawiec
authors.forename: Irena
authors.initials: I
authors.lastname: Federowicz
authors.forename: Jan
authors.initials: J
authors.lastname: Walewski
authors.forename: Joanna
authors.initials: J
authors.lastname: Wegrzyn
authors.forename: Dariusz
authors.initials: D
authors.lastname: Wołowiec
authors.forename: Ewa
authors.initials: E
authors.lastname: Lech-Marańda
authors.forename: Joanna
authors.initials: J
authors.lastname: Sawczuk-Chabin
authors.forename: Przemysław
authors.initials: P
authors.lastname: Biliński
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Warzocha
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000097:blood / Q000276:immunology; D005260:Female; D006388:Hemagglutinins / Q000276:immunology; D006801:Humans; D009980:Influenza A virus / Q000276:immunology; D007252:Influenza Vaccines / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009439:Neuraminidase / Q000276:immunology / Q000378:metabolism; D013997:Time Factors
chemical_list: D000906:Antibodies; D006388:Hemagglutinins; D007252:Influenza Vaccines; D009439:Neuraminidase